3. Heterogeneity of the mortality effects
across studies was noted.
4. A prespecified subgroup analysis
suggested that major CVD
outcome reduction occurred in patients
without known CVD at baseline
(hazard ratio 0.84 [95% CI
0.74–0.94]) (43).
5. Mortality findings in ACCORD (39)
and subgroup analyses of the VADT
(44) suggested that the potential
risks of intensive glycemic control
may outweigh its benefits in some
patients.
6. Those with long duration of diabetes,
known history of severe hypoglycemia,
advanced atherosclerosis, or advanced
age/frailty may benefit from
less aggressive targets.
7. Severe hypoglycemia was signifi-
cantly more likely in participants in
all three trials randomized to the intensive
glycemic control arm